Gordon Research Conferences
Meeting Details
Search:
  GO

Tuberculosis Drug Discovery and Development
Gordon Research Conference

New Approaches, New Chemical Entities and New Targets for Tuberculosis Drugs

Dates

June 25-30, 2017

Location

Renaissance Tuscany Il Ciocco
Lucca (Barga), Italy

Organizers

Chairs:
Courtney C. Aldrich & Tanya Parish

Vice Chairs:
Lluis Ballell-Pages & Helena I. Boshoff

Meeting Description

The 2017 Conference on Tuberculosis Drug Discovery and Development will explore the entire process of drug discovery from clinical development of new drugs for tuberculosis (TB) to the underlying biology of Mycobacterium tuberculosis that impacts drug discovery efforts. The conference will address the unique challenges in TB drug discovery through discussion of clinical trial design, complimentary approaches to identification of lead compounds, vulnerable targets and pathways, host-directed therapies, and non-traditional approaches to TB prevention and treatment. We invite researchers interested in all aspects of drug discovery and development and welcome participants from academia, industry, government and non-governmental organizations. In particular, we invite trainees and scientists from TB-endemic countries to apply, as their contribution to the struggle against TB is especially important. All participants are asked to submit abstracts of their work for presentation as posters, and some abstracts will be chosen for oral presentations. The conference provides the opportunity to interact with colleagues in an informal and intimate atmosphere and is designed to promote extensive discussion. In the past, the meeting has been oversubscribed – please apply early!

Related Meeting

This GRC was held in conjunction with the "Tuberculosis Drug Discovery and Development" Gordon Research Seminar (GRS). Refer to the associated GRS program page for more information.

Contributors

Meeting Program

Sunday
4:00 pm - 8:00 pmArrival and Check-in
6:00 pmDinner
7:30 pm - 7:40 pmWelcome / Introductory Comments by GRC Site Staff
7:40 pm - 9:30 pmKeynote Session: The Need for New Drugs Against Tuberculosis
Discussion Leader: Tanya Parish (Infectious Disease Research Institute, USA)
7:40 pm - 7:50 pmOpening Remarks
7:50 pm - 8:00 pmIntroduction by Discussion Leader
8:00 pm - 8:40 pmGraeme Meintjes (University of Cape Town, South Africa)
"New Drugs for TB: Clinical and Programmatic Needs and Challenges"
8:40 pm - 8:45 pmDiscussion
8:45 pm - 9:25 pmValerie Mizrahi (Institute of Infectious Disease and Molecular Medicine, South Africa)
"Harnessing Biological Insight to Accelerate TB Drug Discovery"
9:25 pm - 9:30 pmDiscussion
Monday
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmChallenges in Clinical Trials and Biomarkers for Tuberculosis
Discussion Leader: Anna Upton (TB Alliance, USA)
9:00 am - 9:05 amIntroduction by Discussion Leader
9:05 am - 9:30 amTerry Blaschke (Stanford University, USA)
"New Facts Regarding, and Novel Approaches to, TB Treatment Adherence: Implications for Clinical Practice and Drug Development"
9:30 am - 9:40 amDiscussion
9:40 am - 10:05 amGerhard Walzl (Stellenbosch University, South Africa)
"Developing Treatment Response Biomarkers"
10:05 am - 10:15 amDiscussion
10:15 am - 10:40 amCoffee Break
10:40 am - 11:05 amDebra Hanna (Critical Path Institute, USA)
"Critical Path to TB Drug Regimens: Integrating Data to Drive Innovation in Translational Science for TB Drug Regimen Development"
11:05 am - 11:15 amDiscussion
11:15 am - 11:40 amGerry Davies (University of Liverpool, United Kingdom)
"PreDiCT-TB: Learning from Preclinical Data"
11:40 am - 11:50 amDiscussion
11:50 am - 12:15 pmRada Savic (University of California, San Francisco, USA)
"One Treatment Regimen Does Not Fit All - Use of Data Science to Guide TB Patient Stratification"
12:15 pm - 12:25 pmDiscussion
12:25 pm - 12:30 pmGeneral Discussion
12:30 pmLunch
1:30 pm - 4:30 pmFree Time
4:30 pm - 6:00 pmPoster Session
6:00 pm - 8:00 pmLead Optimization and Clinical Evaluation
Discussion Leader: Lluis Ballell-Pages (GlaxoSmithKline, Spain)
6:00 pm - 6:05 pmIntroduction by Discussion Leader
6:05 pm - 6:30 pmNader Fotouhi (TB Alliance, USA)
"Towards Safer Oxazolidinones as Components of Universal Regimens for TB"
6:30 pm - 6:40 pmDiscussion
6:40 pm - 7:05 pmVadim Makarov (A.N. Bach Institute of Biochemistry, Russian Academy of Sciences, Russia)
"Clinical Trials with the Novel Drug Candidate PBTZ169"
7:05 pm - 7:15 pmDiscussion
7:15 pm - 7:40 pmDavid Barros (GlaxoSmithKline R&D, Spain)
"GSK070: From Bench to Man. A Novel Clinical Candidate for the Treatment of Tuberculosis"
7:40 pm - 7:50 pmDiscussion
7:50 pm - 8:00 pmGeneral Discussion
8:00 pmDinner
Tuesday
7:30 am - 8:30 amBreakfast
8:30 amGroup Photo
9:00 am - 12:30 pmHit-to-Lead Optimization and Pharmacokinetics in Early Drug Discovery
Discussion Leader: Kelly Chibale (University of Cape Town, South Africa)
9:00 am - 9:10 amIntroduction by Discussion Leader
9:10 am - 9:35 amJeffrey Aube (University of North Carolina at Chapel Hill, USA)
"Seeking TB-Active Cephalosporins"
9:35 am - 9:45 amDiscussion
9:45 am - 10:10 amJason Sello (Brown University, USA)
"Beyond the Conventional: Novel Molecules and Strategies for the Treatment of Tuberculosis"
10:10 am - 10:20 amDiscussion
10:20 am - 10:50 amCoffee Break
10:50 am - 11:05 amSelected from Poster Abstracts: Samantha Wellington (Harvard University, USA)
"Identification of a Specific, Allosteric Small-Molecule Inhibitor of Mycobacterium tuberculosis Tryptophan Synthase"
11:05 am - 11:10 amDiscussion
11:10 am - 11:35 amBenoit Deprez (Institut Pasteur, France)
"Outsmarting Resistance in Tuberculosis SMARt Compounds: From Lead to Drug Candidate"
11:35 am - 11:45 amDiscussion
11:45 am - 12:10 pmCynthia Dowd (George Washington University, USA)
"Hitting Malaria and Tuberculosis with the Same Bullet? Dxr Inhibitors as Antimicrobials"
12:10 pm - 12:20 pmDiscussion
12:20 pm - 12:30 pmGeneral Discussion
12:30 pmLunch
1:30 pm - 4:30 pmFree Time
4:30 pm - 6:00 pmPoster Session
6:00 pm - 8:00 pmNatural Products in Antibacterial Discovery
Discussion Leader: Ronald Quinn (Griffith University, Australia)
6:00 pm - 6:05 pmIntroduction by Discussion Leader
6:05 pm - 6:30 pmSean Brady (Rockefeller University, USA)
"Culture Independent Approaches for the Discovery of New Antibiotics"
6:30 pm - 6:40 pmDiscussion
6:40 pm - 7:05 pmSylvie Garneau-Tsodikova (University of Kentucky, USA)
"Novel Aminoglycoside Adjuvants and Stand-Alone Agents to Combat Tuberculosis"
7:05 pm - 7:15 pmDiscussion
7:15 pm - 7:40 pmNathan Magarvey (McMaster University, Canada)
"Clustering and Assembly of Genetically Inferred Antibiotics"
7:40 pm - 7:50 pmDiscussion
7:50 pm - 8:00 pmGeneral Discussion
8:00 pmDinner
Wednesday
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmMetabolism as a Target
Discussion Leader: Luiz Pedro Carvalho (Francis Crick Institute, United Kingdom)
9:00 am - 9:05 amIntroduction by Discussion Leader
9:05 am - 9:30 amLaura Kiessling (University of Wisconsin-Madison, USA)
"Chemical Probes of Cell Envelope Biosynthesis"
9:30 am - 9:40 amDiscussion
9:40 am - 10:05 amLindsay Eltis (University of British Columbia, Canada)
"Cholesterol Catabolism - A Ring-Side Seat"
10:05 am - 10:15 amDiscussion
10:15 am - 10:45 amCoffee Break
10:45 am - 11:10 amAnthony Baughn (University of Minnesota, USA)
"Stress Response as a Driver of Pyrazinamide Susceptibility"
11:10 am - 11:20 amDiscussion
11:20 am - 11:35 amSelected from Poster Abstracts: Dany Beste (University of Surrey, United Kingdom)
"Intracellular Mycobacterium tuberculosis Requires Two Gateways into Gluconeogenesis and Multiple CO2 Fixation Routes"
11:35 am - 11:40 amDiscussion
11:40 am - 12:05 pmNagasuma Chandra (Indian Institute of Science, India)
"Reversing Antibiotic Resistance Through Strategic Combinations"
12:05 pm - 12:15 pmDiscussion
12:15 pm - 12:30 pmGeneral Discussion
12:30 pmLunch
1:30 pm - 4:30 pmFree Time
4:30 pm - 6:00 pmPoster Session
6:00 pm - 8:00 pmPromiscuous Targets, Drugs, and Hits
Discussion Leader: Kevin Pethe (Lee Kong Chian School of Medicine, Nanyang Technologicial University, Singapore)
6:00 pm - 6:05 pmIntroduction by Discussion Leader
6:05 pm - 6:30 pmJonathan Baell (Monash University, Australia)
"Resource-Wasting Pan Assay Interference Compounds (PAINS): Readily Found in Any Screen and Highly Relevant to TB Drug Discovery"
6:30 pm - 6:35 pmDiscussion
6:35 pm - 7:00 pmAdrie Steyn (Kwazulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), South Africa)
"Bioenergetic Rewiring: Turning the Respiratory Flexibility of M. tuberculosis Against Itself"
7:00 pm - 7:05 pmDiscussion
7:05 pm - 7:20 pmSelected from Poster Abstracts: Erik Hasenoehrl (Albert Einstein College of Medicine, USA)
"Cytochrome bd Oxidase and the CydDC Transporter: New Drug Targets at the Heart of Redox Homeostasis in Mycobacterium tuberculosis"
7:20 pm - 7:25 pmDiscussion
7:25 pm - 7:50 pmMary Jackson (Colorado State University, USA)
"MmpL3: Therapeutic Potential and Mechanism of Inhibition"
7:50 pm - 7:55 pmDiscussion
7:55 pm - 8:00 pmGeneral Discussion
8:00 pmDinner
Thursday
7:30 am - 8:30 amBreakfast
8:30 am - 9:00 amBusiness Meeting
Nominations for the Next Vice Chair; Fill in Conference Evaluation Forms; Discuss Future Site and Scheduling Preferences; Election of the Next Vice Chair
9:00 am - 12:30 pmHost-Directed Therapies and Host-Pathogen Interactions
Discussion Leader: Gilla Kaplan (Bill & Melinda Gates Foundation, USA)
9:00 am - 9:10 amIntroduction by Discussion Leader
9:10 am - 9:35 amPriscille Brodin (INSERM / Institut Pasteur de Lille, France)
"Investigation of a Drug Candidate with Enhanced Potency Against Intracellular M. tuberculosis"
9:35 am - 9:45 amDiscussion
9:45 am - 10:10 amRobert Abramovitch (Michigan State University, USA)
"Small Molecules that Inhibit Mycobacterium tuberculosis Environmental Sensing and Virulence"
10:10 am - 10:20 amDiscussion
10:20 am - 10:50 amCoffee Break
10:50 am - 11:15 amLate-Breaking Topic
11:15 am - 11:25 amDiscussion
11:25 am - 11:40 amVeronique Fontaine (Université Libre de Bruxelles, Belgium)
"Investigation of the Role of GroEL-1 and PDIM in Antibiotic Resistance leads to Repurpose Drugs as Antimycobacterial Candidates"
11:40 am - 11:45 amDiscussion
11:45 am - 12:10 pmThomas Hawn (University of Washington, USA)
"Host-Directed Therapies in Macrophages and TB"
12:10 pm - 12:20 pmDiscussion
12:20 pm - 12:30 pmGeneral Discussion
12:30 pmLunch
1:30 pm - 4:30 pmFree Time
4:30 pm - 6:00 pmPoster Session
6:00 pm - 8:00 pmOutside the Norm: Non-Traditional Approaches
Discussion Leader: Helena Boshoff (National Institutes of Health, USA)
6:00 pm - 6:05 pmIntroduction by Discussion Leader
6:05 pm - 6:30 pmNitin Baliga (Institute for Systems Biology, USA)
"Network Strategy to Accelerate Discovery of Combination Therapy Against Drug Resistance in TB"
6:30 pm - 6:40 pmDiscussion
6:40 pm - 6:55 pmSelected from Poster Abstracts: Yesha Patel (Indian Institute of Technology, Bombay, India)
"Oxidative Stress: A Potential Target for Combination Therapy Against Mycobacteria"
6:55 pm - 7:00 pmDiscussion
7:00 pm - 7:15 pmSelected from Poster Abstracts: Magdalena Bielecka (University of Southampton, United Kingdom)
"A Bioengineered 3-Dimensional Cell Culture Platform for Developing Novel Therapeutic Approaches for Tuberculosis"
7:15 pm - 7:20 pmDiscussion
7:20 pm - 7:45 pmGiulia Manina (Institut Pasteur, France)
"Targeting Phenotypic Variation in Mycobacteria to Improve Drug-Mediated Killing"
7:45 pm - 7:55 pmDiscussion
7:55 pm - 8:00 pmClosing Remarks
8:00 pmDinner
Friday
7:30 am - 8:30 amBreakfast
9:00 amDeparture

Funding for this conference was made possible [in part] by 1 R13 AI 131575 - 01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
© 2017 Gordon Research Conferences Search | Contact | Terms of Use | Privacy Policy | Follow us: Facebook Twitter